PACIRA BIOSCIENCES, INC. Share Repurchase Program Excise Tax
PACIRA BIOSCIENCES, INC. (PCRX) reported Share Repurchase Program Excise Tax of $400.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Notes › Equity
us-gaap:ShareRepurchaseProgramExciseTax · last filed 2026-08-04
- PACIRA BIOSCIENCES, INC. share repurchase program excise tax for the quarter ending 2026-06-30 was $0.00.
- PACIRA BIOSCIENCES, INC. share repurchase program excise tax for the quarter ending 2026-03-31 was $400.00K.
- PACIRA BIOSCIENCES, INC. share repurchase program excise tax for the quarter ending 2025-12-31 was $1.00M.
- PACIRA BIOSCIENCES, INC. share repurchase program excise tax for the quarter ending 2025-09-30 was -$100.00K.
- PACIRA BIOSCIENCES, INC. share repurchase program excise tax for fiscal 2025 was $1.30M.
| Period end | Share Repurchase Program Excise Tax | Share Repurchase Program Excise Tax 3 month | Share Repurchase Program Excise Tax 6 month | Share Repurchase Program Excise Tax 9 month | Share Repurchase Program Excise Tax 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | $400.00K 10-Q · filed 2026-08-04 | $1.40M derived: sum of 3 quarters · filed 2026-08-04 | $1.30M derived: sum of 4 quarters · filed 2026-08-04 | |
| 2026-03-31 | $400.00K 10-Q · filed 2026-04-30 | $1.40M derived: sum of 2 quarters · filed 2026-04-30 | $1.30M derived: sum of 3 quarters · filed 2026-04-30 | ||
| 2025-12-31 | $1.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $900.00K derived: sum of 2 quarters · filed 2026-02-26 | $1.30M 10-K · filed 2026-02-26 | ||
| 2025-09-30 | -$100.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $300.00K 10-Q · filed 2025-11-06 | |||
| 2025-06-30 | $400.00K 10-Q · filed 2025-08-05 | ||||
| 2024-05-10 | $100.00K 10-K · filed 2026-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |